Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application
Abdelhafeez, H., El-Zaher, A., Ahmed-Farid, O., badawi, M., Tarek, S. (2024). Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application. EKB Journal Management System, 67(12), 37-46. doi: 10.21608/ejchem.2024.280457.9538
Heba Abdelhafeez; Asmaa El-Zaher; Omar Ahmed-Farid; mohamed badawi; Sally Tarek. "Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application". EKB Journal Management System, 67, 12, 2024, 37-46. doi: 10.21608/ejchem.2024.280457.9538
Abdelhafeez, H., El-Zaher, A., Ahmed-Farid, O., badawi, M., Tarek, S. (2024). 'Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application', EKB Journal Management System, 67(12), pp. 37-46. doi: 10.21608/ejchem.2024.280457.9538
Abdelhafeez, H., El-Zaher, A., Ahmed-Farid, O., badawi, M., Tarek, S. Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application. EKB Journal Management System, 2024; 67(12): 37-46. doi: 10.21608/ejchem.2024.280457.9538

Proper retention factor for Avanafil and Dapoxetine Hydrochloride Separation and Validation with RP-HPLC in Bulk, Dosage Form and Rat Plasma; Validation, Degradation, and Pharmacokinetic Application

Egyptian Journal of Chemistry
Volume 67, Issue 12, December 2024, Page 37-46  XML PDF (839.3 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2024.280457.9538
View on SCiNiTO View on SCiNiTO
Authors
Heba Abdelhafeez email orcid 1; Asmaa El-Zaher2; Omar Ahmed-Faridorcid 3; mohamed badawi4; Sally Tarekorcid 5
1Researcher of PC3 Egyptian Drug Authority
2Faculty of Pharmacy, Cairo University
3Associate professor of Physiology
4Lecturer Egyptian drug authority
5Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, P.O. Box 11562.
Abstract
Environmental changes and fluctuated storage conditions are the main markers for API degradation and drug-drug interactions. Avanafil (Ava), phosphodiesterase inhibitor and dapoxetine (Dap), selective serotonin reuptake inhibitor helps to treat erectile dysfunction and increase ejaculation retention. The aim of the current study is to investigate the best chromatographic condition for the determination of Ava, Dap and their degradation products at different stress conditions and develop a sensitive, rapid, and reproducible method for their simultaneous estimation either in their combined dosage form or in rat plasma. The chromatographic conditions involve separation with RP-Eclipse-XDP C18 column, (25 cm ×4.6 mm, 5µ) column at 239 nm detection wavelength and mobile phase consisting of buffer (phosphate, pH 3) to acetonitrile with ratio 55:45 (v/v) and the injection volume was 20 µl. The method was subsequently used to evaluate the mixture of Ava and Dap pharmacokinetics in rat plasma. The pharmacokinetic parameters Cmax, Tmax, t1/2, AUC0- 24, AUCtotal, Ke, Vd, and CL of the cited drugs after oral administration was determined. The obtained data demonstrate that the method was applied successfully for separating each component and their degradation products with all accepted validation parameters and the method can be applied for preclinical pharmacokinetic investigation.
Keywords
Avanafil; dapoxetine; degradation; HPLC; UV detector; and pharmacokinetics
Supplementary Files
Statistics
Article View: 531
PDF Download: 410